Versatile Bioadhesives

Solicitation ARPA-H 02, issued by the Department of Health and Human Services under ARPA-H, seeks the development of next-generation bioadhesive platforms designed to seal, bond, and repair tissues in challenging clinical environments, such as wet or bloody conditions. These platforms should offer strong adhesion, biocompatibility, controlled degradation, and reversibility, with the potential to deliver biologics or small molecules. The goal is to improve patient outcomes through enhanced hemostasis, leak prevention, and tissue repair. This is a Total Small Business Set-Aside under NAICS code 325520, structured as a Phase I SBIR/STTR effort with potential extensions into Phase II and Sequential Phase II, lasting up to 24 and 36 months respectively. Applicants must submit a solution summary limited to four pages, a key personnel worksheet, and a cost proposal. Those advancing to the oral technical presentation must provide a task description document, a Gantt chart, and a 16-slide presentation focusing on technical merit, novelty, and a commercialization plan. Evaluation is based on the ARPA-H Heilmeier Questions, emphasizing transformative health advancements and equitable access. The contract incorporates various FAR and HHSAR clauses, including specific deviations regarding representations and certifications, and requires electronic payment via the Department of Treasury Invoice Processing Platform. Technical deliverables must comply with Revised 508 Standards for accessibility.